AU2022262777C1 - Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same - Google Patents

Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same Download PDF

Info

Publication number
AU2022262777C1
AU2022262777C1 AU2022262777A AU2022262777A AU2022262777C1 AU 2022262777 C1 AU2022262777 C1 AU 2022262777C1 AU 2022262777 A AU2022262777 A AU 2022262777A AU 2022262777 A AU2022262777 A AU 2022262777A AU 2022262777 C1 AU2022262777 C1 AU 2022262777C1
Authority
AU
Australia
Prior art keywords
compound
cancer
amino
nnh
furan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022262777A
Other languages
English (en)
Other versions
AU2022262777A1 (en
AU2022262777B2 (en
Inventor
Dalyong GWAK
Hyunjin Michael KIM
Chang Sik Lee
Jae Young Lee
Jaewon Lee
Yesong PARK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of AU2022262777A1 publication Critical patent/AU2022262777A1/en
Application granted granted Critical
Publication of AU2022262777B2 publication Critical patent/AU2022262777B2/en
Publication of AU2022262777C1 publication Critical patent/AU2022262777C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022262777A 2021-04-23 2022-04-21 Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same Active AU2022262777C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2021-0053352 2021-04-23
KR20210053352 2021-04-23
PCT/IB2022/053721 WO2022224180A1 (en) 2021-04-23 2022-04-21 Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same

Publications (3)

Publication Number Publication Date
AU2022262777A1 AU2022262777A1 (en) 2023-09-21
AU2022262777B2 AU2022262777B2 (en) 2024-11-07
AU2022262777C1 true AU2022262777C1 (en) 2025-02-13

Family

ID=83722733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022262777A Active AU2022262777C1 (en) 2021-04-23 2022-04-21 Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same

Country Status (11)

Country Link
US (1) US20240217978A1 (https=)
EP (1) EP4326724A4 (https=)
JP (1) JP7646873B2 (https=)
KR (1) KR102863028B1 (https=)
CN (1) CN117120443A (https=)
AU (1) AU2022262777C1 (https=)
BR (1) BR112023021918A2 (https=)
CA (1) CA3207935A1 (https=)
MX (1) MX2023012338A (https=)
TW (1) TWI838736B (https=)
WO (1) WO2022224180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023296161A1 (en) * 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048163A1 (en) * 2001-11-30 2003-06-12 Schering Corporation [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459702A1 (en) * 1990-05-29 1991-12-04 Zeneca Limited Azole Derivatives
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6664252B2 (en) * 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JPWO2003068776A1 (ja) * 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
EP3810610A1 (en) * 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
JP7197206B2 (ja) * 2018-06-26 2022-12-27 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体
AU2019383948A1 (en) * 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CN112028891B (zh) * 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048163A1 (en) * 2001-11-30 2003-06-12 Schering Corporation [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
JP2024515739A (ja) 2024-04-10
JP7646873B2 (ja) 2025-03-17
KR102863028B1 (ko) 2025-09-22
WO2022224180A1 (en) 2022-10-27
TW202302593A (zh) 2023-01-16
BR112023021918A2 (pt) 2023-12-19
AU2022262777A1 (en) 2023-09-21
MX2023012338A (es) 2023-10-30
US20240217978A1 (en) 2024-07-04
CN117120443A (zh) 2023-11-24
TWI838736B (zh) 2024-04-11
AU2022262777B2 (en) 2024-11-07
EP4326724A4 (en) 2025-03-26
CA3207935A1 (en) 2022-10-27
EP4326724A1 (en) 2024-02-28
KR20220146348A (ko) 2022-11-01

Similar Documents

Publication Publication Date Title
AU2021218041B2 (en) Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
CN102711473B (zh) 布鲁顿酪氨酸激酶抑制剂
AU2019313441B2 (en) TLR7/8 antagonists and uses thereof
CN109153665B (zh) 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
AU2018303080B2 (en) Peptide amide compound and preparation method and medical use thereof
EP3400221B1 (en) Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
AU2018363771A1 (en) Novel sulfonamide carboxamide compounds
AU2023358081A1 (en) Novel bicyclic heterocyclyl compounds and use thereof
US11332459B2 (en) Benzimidazole derivatives and their uses
CA2957048A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2024203782A1 (en) Antiviral pyrazolopyridinone compounds
KR101710127B1 (ko) 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
AU2022262777C1 (en) Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same
WO2024054954A1 (en) Heterobifunctional compounds and methods of treating disease
AU2023225842A1 (en) Fused bicyclic compound containing pyrrolinone
AU2020374041A1 (en) EED inhibitor, and preparation method therefor and use thereof
RU2840068C2 (ru) СОЕДИНЕНИЕ В КАЧЕСТВЕ АНТАГОНИСТА АДЕНОЗИНОВОГО РЕЦЕПТОРА A2a И СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
HK40097855A (zh) 作为腺苷a2a受体拮抗剂的化合物及包含其的药物组合物
AU2023306869A1 (en) Wee1 inhibitor, preparation therefor and use thereof
TW202506681A (zh) Myc家族原癌基因蛋白之調節劑

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 NOV 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 07 NOV 2024

FGA Letters patent sealed or granted (standard patent)